))
COVID-19 and Pharmaceuticals In Canada
Manage episode 318330336 series 2937012
Content provided by Connex Health Consulting. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Connex Health Consulting or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
We are pleased to welcome Cole Pinnow, President of Pfizer Canada and the recently appointed Chair of the Board for Innovative Medicines Canada to this podcast. Mr. Pinnow has a background as a microbiologist in the pharmaceutical industry and a masters in business administration. He is also a Board member of Montreal InVivo, and a co-lead for the Canadian Chamber of Commerce’s COVID-19 Recovery Leadership Council.
In this podcast, Mr. Pinnow provides insights into lessons learned about how Canada and the pharmaceutical sector have responded to the pandemic and the lingering impact of the ‘shadow’ pandemic. He answers questions about healthcare resiliency and the impact of chronic disease, specialty drugs and drugs for rare diseases on patients and plan sponsors. Plus he makes comment on the opportunities and benefits of collaboration between research based pharmaceutical companies and insurers.
Join us for these and more fascinating insights. This podcast is free. Thank you to our season sponsors for the Benefits Breakfast Club for making this podcast possible.
--
Find out more information on upcoming podcasts and webinars at www.connexhc.com.
41 episodes
Share
